Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
花旗製藥公司(Citius PharmPharmticals，Inc.)(以下稱“Citius”或“公司”)(納斯達克股票代碼：CTXR)是一家晚期生物製藥公司，致力於一流重症監護產品的開發和商業化，重點是腫瘤學、附屬癌症護理中的抗感染產品、獨特的處方藥產品和幹細胞療法。該公司今天宣佈，將在2021年10月的兩個投資者大會上發言。
EVENT: Benzinga Rising Stars: Catalytic Small Cap Growth Conference DATE: Thursday, October 7, 2021 Citius Executive Chairman Leonard Mazur will present at 9:05 a.m. ET. His presentation will be available for viewing on Benzinga's live stream channel.
活動：本辛加後起之秀：催化小盤股增長大會日期：2021年10月7日(星期四)花旗執行主席倫納德·馬祖爾(Leonard Mazur)將於上午9：05出席。Et.他的演講將在Benzinga的直播頻道上觀看。
EVENT: Dawson James Securities 6th Annual Small Cap Growth Conference DATE: Thursday, October 21, 2021 Citius Executive Chairman Leonard Mazur will present at 8:55 a.m. ET in Track 1 and will be available for 1-on-1 meetings with registered conference attendees. The conference will be held October 20-21 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. A webcast of the presentation will be available on the Events page of the Citius Investors website.
事件：道森·詹姆斯證券公司(Dawson James Securities)第六屆年度小盤股增長大會日期：2021年10月21日(星期四)花旗執行主席倫納德·馬祖爾(Leonard Mazur)將於上午8點55分出席。ET在軌道1中，將可用於與已註冊的與會者進行一對一會議。會議將於10月20日至21日在佛羅里達州朱庇特市海濱廣場的温德姆大木星酒店舉行。演示文稿的網絡直播將在Citius Investors網站的活動頁面上進行。
At the conferences, Mr. Mazur will discuss the Company's growing pipeline of therapies targeting unmet medical needs consisting of two late-stage assets completing Phase 3 trials, three potential first-and-only prescription treatments in their indications, and a next-generation stem cell therapy program.
在會議上，馬祖爾先生將討論該公司針對未得到滿足的醫療需求的日益增長的治療流水線，其中包括完成第三階段試驗的兩項晚期資產、三種潛在的第一種也是唯一一種適應症處方藥，以及下一代幹細胞治療計劃。
About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok(R), an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok(R) was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Citius製藥公司簡介Citius是一家晚期生物製藥公司，致力於一流危重護理產品的開發和商業化，重點是腫瘤學、輔助癌症護理中的抗感染藥物、獨特的處方藥和幹細胞療法。該公司有兩個後期候選產品：Mino-Lok(R)和I/Ontak(E7777)。Mino-Lok(R)是一種用於治療導管相關血流感染(CRBSI)患者的抗生素鎖定解決方案，目前正在招募患者參加第三階段關鍵優勢試驗；I/Ontak(E7777)是一種用於皮膚T細胞淋巴瘤(CTCL)初步適應症的新型IL-2R免疫療法，它已經完成了其關鍵第三階段試驗的登記。Mino-Lok(R)獲得美國食品和藥物管理局(FDA)的快速通道稱號。I/Ontak已獲得FDA指定的治療CTCL和外周T細胞淋巴瘤(PTCL)的孤兒藥物。通過其子公司NoveCite公司，花旗公司正在開發一種從誘導多能幹細胞中提取的治療急性呼吸疾病的新型專利間充質幹細胞療法，近期的重點是治療與新冠肺炎有關的急性呼吸窘迫綜合徵。欲瞭解更多信息，請訪問www.citiuspharma.com。
Investor Relations for Citius Pharmaceuticals: Ilanit Allen Vice President, Investor Relations and Corporate Communications T: 908-967-6677 x113 E: ir@citiuspharma.com
投資者關係和公司通聯部副總裁伊蘭尼特·艾倫(Ilanit Allen)電話：908-967-6677 x113電子郵件：ir@citiuspharma.com
https://mma.prnewswire.com/media/1593817/Citius_Logo.jpg
Https://mma.prnewswire.com/media/1593817/Citius_Logo.jpg
https://c212.net/c/img/favicon.png?sn=NE31297&sd=2021-10-06
Https://c212.net/c/img/favicon.png?sn=NE31297&sd=2021-10-06
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-upcoming-october-investor-conferences-301394276.html
查看原創內容以下載multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-upcoming-october-investor-conferences-301394276.html
SOURCE Citius Pharmaceuticals, Inc.
資料來源：花旗製藥公司(Citius PharmPharmticals，Inc.)
https://rt.prnewswire.com/rt.gif?NewsItemId=NE31297&Transmission_Id=202110061040PR_NEWS_USPR_____NE31297&DateId=20211006
Https://rt.prnewswire.com/rt.gif?NewsItemId=NE31297&Transmission_Id=202110061040PR_NEWS_USPR_NE31297&DateId=20211006
COMTEX_394670182/1005/2021-10-06T10:40:32
COMETX_394670182/1005/2021-10-06T10：40：32
譯文內容由第三人軟體翻譯。